JPMorgan Chase Cuts Neurocrine Biosciences Price Target

Analysts lower price target on biotech company's stock to $176 per share

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has lowered its price target for Neurocrine Biosciences (NASDAQ:NBIX) from $177 to $176 per share, while maintaining an overweight rating on the stock. The biotech company, based in San Diego, California, is focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.

Why it matters

Neurocrine Biosciences' lead marketed product is Ingrezza, which is used to treat tardive dyskinesia, a movement disorder associated with long-term antipsychotic use. The company's stock price and valuation are closely watched by investors as it continues to develop new treatments for unmet medical needs in the central nervous system.

The details

In a research note, JPMorgan Chase analysts trimmed their price target on Neurocrine Biosciences from $177 to $176 per share, while keeping an overweight rating on the stock. Several other research firms have also recently weighed in on NBIX, with Piper Sandler raising its price target to $179 and UBS Group lowering its target to $178. The company reported earnings of $1.88 per share in its latest quarter, missing the consensus estimate of $2.36.

  • Neurocrine Biosciences reported earnings on February 11, 2026.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Neurocrine Biosciences

A biopharmaceutical company based in San Diego, California that focuses on developing treatments for neurological, endocrine and neuropsychiatric disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This price target adjustment by JPMorgan Chase reflects the ongoing scrutiny and analysis of Neurocrine Biosciences' pipeline and commercial performance as the company continues to develop new treatments for central nervous system disorders.